These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 30477834)

  • 1. Effects of lipoic acid on walking performance, gait, and balance in secondary progressive multiple sclerosis.
    Loy BD; Fling BW; Horak FB; Bourdette DN; Spain RI
    Complement Ther Med; 2018 Dec; 41():169-174. PubMed ID: 30477834
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Erratum.
    Mult Scler; 2016 Oct; 22(12):NP9-NP11. PubMed ID: 26041800
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lipoic Acid Stimulates cAMP Production in Healthy Control and Secondary Progressive MS Subjects.
    Fiedler SE; Yadav V; Kerns AR; Tsang C; Markwardt S; Kim E; Spain R; Bourdette D; Salinthone S
    Mol Neurobiol; 2018 Jul; 55(7):6037-6049. PubMed ID: 29143287
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The effectiveness of Robot-Assisted Gait Training versus conventional therapy on mobility in severely disabled progressIve MultiplE sclerosis patients (RAGTIME): study protocol for a randomized controlled trial.
    Straudi S; Manfredini F; Lamberti N; Zamboni P; Bernardi F; Marchetti G; Pinton P; Bonora M; Secchiero P; Tisato V; Volpato S; Basaglia N
    Trials; 2017 Feb; 18(1):88. PubMed ID: 28241776
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Gastrointestinal Tolerability and Absorption of R- Versus R,S-Lipoic Acid in Progressive Multiple Sclerosis: A Randomized Crossover Trial.
    Cameron M; Taylor C; Lapidus J; Ramsey K; Koop D; Spain R
    J Clin Pharmacol; 2020 Aug; 60(8):1099-1106. PubMed ID: 32212340
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rehabilitation with neuromuscular electrical stimulation leads to functional gains in ambulation in patients with secondary progressive and primary progressive multiple sclerosis: a case series report.
    Wahls TL; Reese D; Kaplan D; Darling WG
    J Altern Complement Med; 2010 Dec; 16(12):1343-9. PubMed ID: 21138391
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Utility of the Six-Spot Step Test as a Measure of Walking Performance in Ambulatory Individuals With Multiple Sclerosis.
    Fritz NE; Jiang A; Keller J; Zackowski KM
    Arch Phys Med Rehabil; 2016 Apr; 97(4):507-512. PubMed ID: 26577146
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Cannabinoid Use in Progressive Inflammatory brain Disease (CUPID) trial: a randomised double-blind placebo-controlled parallel-group multicentre trial and economic evaluation of cannabinoids to slow progression in multiple sclerosis.
    Ball S; Vickery J; Hobart J; Wright D; Green C; Shearer J; Nunn A; Cano MG; MacManus D; Miller D; Mallik S; Zajicek J
    Health Technol Assess; 2015 Feb; 19(12):vii-viii, xxv-xxxi, 1-187. PubMed ID: 25676540
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of natalizumab on disease progression in secondary progressive multiple sclerosis (ASCEND): a phase 3, randomised, double-blind, placebo-controlled trial with an open-label extension.
    Kapoor R; Ho PR; Campbell N; Chang I; Deykin A; Forrestal F; Lucas N; Yu B; Arnold DL; Freedman MS; Goldman MD; Hartung HP; Havrdová EK; Jeffery D; Miller A; Sellebjerg F; Cadavid D; Mikol D; Steiner D;
    Lancet Neurol; 2018 May; 17(5):405-415. PubMed ID: 29545067
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Oral fingolimod in primary progressive multiple sclerosis (INFORMS): a phase 3, randomised, double-blind, placebo-controlled trial.
    Lublin F; Miller DH; Freedman MS; Cree BAC; Wolinsky JS; Weiner H; Lubetzki C; Hartung HP; Montalban X; Uitdehaag BMJ; Merschhemke M; Li B; Putzki N; Liu FC; Häring DA; Kappos L;
    Lancet; 2016 Mar; 387(10023):1075-1084. PubMed ID: 26827074
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Association between dual task-related decrease in walking speed and real versus imagined Timed Up and Go test performance.
    Bridenbaugh SA; Beauchet O; Annweiler C; Allali G; Herrmann F; Kressig RW
    Aging Clin Exp Res; 2013 Jun; 25(3):283-9. PubMed ID: 23740587
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Instrumented balance and walking assessments in persons with multiple sclerosis show strong test-retest reliability.
    Craig JJ; Bruetsch AP; Lynch SG; Horak FB; Huisinga JM
    J Neuroeng Rehabil; 2017 May; 14(1):43. PubMed ID: 28532417
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The EDSS-Plus, an improved endpoint for disability progression in secondary progressive multiple sclerosis.
    Cadavid D; Cohen JA; Freedman MS; Goldman MD; Hartung HP; Havrdova E; Jeffery D; Kapoor R; Miller A; Sellebjerg F; Kinch D; Lee S; Shang S; Mikol D
    Mult Scler; 2017 Jan; 23(1):94-105. PubMed ID: 27003945
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Two Different Types of High-Frequency Physical Therapy Promote Improvements in the Balance and Mobility of Persons With Multiple Sclerosis.
    Davies BL; Arpin DJ; Liu M; Reelfs H; Volkman KG; Healey K; Zabad R; Kurz MJ
    Arch Phys Med Rehabil; 2016 Dec; 97(12):2095-2101.e3. PubMed ID: 27373745
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The effects of robot-assisted gait training in progressive multiple sclerosis: A randomized controlled trial.
    Straudi S; Fanciullacci C; Martinuzzi C; Pavarelli C; Rossi B; Chisari C; Basaglia N
    Mult Scler; 2016 Mar; 22(3):373-84. PubMed ID: 26658817
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Randomized clinical trial of balance-based torso weighting for improving upright mobility in people with multiple sclerosis.
    Widener GL; Allen DD; Gibson-Horn C
    Neurorehabil Neural Repair; 2009 Oct; 23(8):784-91. PubMed ID: 19470807
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Psychometric Properties of a Core Set of Measures of Balance for People With Cerebellar Ataxia Secondary to Multiple Sclerosis.
    Winser S; Smith CM; Hale LA; Claydon LS; Whitney SL; Klatt B; Mottershead J; Zaydan I; Heyman R
    Arch Phys Med Rehabil; 2017 Feb; 98(2):270-276. PubMed ID: 27577181
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mitoxantrone: a review of its use in multiple sclerosis.
    Scott LJ; Figgitt DP
    CNS Drugs; 2004; 18(6):379-96. PubMed ID: 15089110
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Free-living and laboratory gait characteristics in patients with multiple sclerosis.
    Storm FA; Nair KPS; Clarke AJ; Van der Meulen JM; Mazzà C
    PLoS One; 2018; 13(5):e0196463. PubMed ID: 29715279
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Chronic venous disorders and injection drug use: impact on balance, gait, and walk speed.
    Pieper B; Templin TN; Birk TJ; Kirsner RS
    J Wound Ostomy Continence Nurs; 2008; 35(3):301-10. PubMed ID: 18496087
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.